Navigation Links
Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
Date:5/30/2013

DALLAS, May 30, 2013 /PRNewswire/ -- Securities lawyers at Deans & Lyons announced an investigation of the board of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) for a proposed sale to AstraZeneca. OMTH investors are encouraged to contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.

Although at least one analyst estimated the value could reach $15 per share before the deal was announced, OMTH stockholders will receive only $12.70 per share upon the acquisition by AstraZeneca. The investigation seeks to ensure OMTH stockholders obtain the highest price reasonably available in this buyout in addition to the disclosure of all important information.

The securities lawyers of Deans & Lyons have significant experience representing investors nationwide in representative actions involving securities at no cost to its clients.  Stockholders with concerns about this OMTH stock or anyone with information about this transaction should contact Hamilton Lindley at hlindley@deanslyons.com or 877-819-8033.

Hamilton Lindley
Deans & Lyons LLP
325 N. Saint Paul Street , Suite 1500
Dallas, TX 75201
(877) 819-8033 Toll Free
(214) 965-8500 Telephone
(214) 965-8505 Facsimile
hlindley@deanslyons.com
deanslyons.com


'/>"/>
SOURCE Deans & Lyons LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
2. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
3. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
4. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
5. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
6. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
9. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
10. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
11. Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/23/2017)... 2017  Leaf Healthcare, recognized for developing one ... pressure ulcer prevention, will unveil its comprehensive mobility ... Care Nurses, National Teaching Institute and Critical Care ... Leaf Patient Monitoring System is the first mobility ... The system seamlessly tracks patient movement throughout the ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... ... , ... Guide to FDA and EU Medical Device Regulations: 2017 Edition, **An ... the Atlantic devicemakers do business, this fully updated and expanded guide keeps them in ... the full text of the FDA’s regulations in 21 CFR Parts 800 to 898, ...
(Date:6/28/2017)... ... ... control has seen the never-ending twists on the house flipping show genre. The shows promote ... But what about the buyers of the flipper's flip. , Here is an ... An email recently sent to Gary Case said, “Just closed on a home on Capitol ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold & ... for the Illinois State Bar Association , in accordance with the organization’s rules of ... following a state-wide election and served in that capacity for the past year prior to ...
(Date:6/28/2017)... , ... June 28, 2017 , ... American Farmer proudly ... episode of the award winning television series, scheduled to broadcast fourth quarter 2017. American ... originated as a regional supplier of garden pea seed. As demand grew, the small ...
Breaking Medicine News(10 mins):